Quarterly Consolidated Statement Of Cash Flows

Immuno-Biological Laboratories Co., Ltd. - Filing #7370747

Concept As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
As at
2022-09-30
2022-04-01 to
2022-09-30
As at
2022-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
29,869,000 JPY
-131,581,000 JPY
Impairment losses
602,000 JPY
804,000 JPY
Increase (decrease) in allowance for doubtful accounts
-6,697,000 JPY
JPY
Interest and dividend income
-47,000 JPY
-630,000 JPY
Interest expenses
533,000 JPY
536,000 JPY
Foreign exchange losses (gains)
-2,820,000 JPY
-3,191,000 JPY
Share of loss (profit) of entities accounted for using equity method
JPY
90,359,000 JPY
Decrease (increase) in trade receivables
24,935,000 JPY
22,460,000 JPY
Decrease (increase) in inventories
-6,904,000 JPY
-20,396,000 JPY
Increase (decrease) in trade payables
-2,298,000 JPY
-309,000 JPY
Other, net
-13,617,000 JPY
4,128,000 JPY
Subtotal
16,920,000 JPY
-41,810,000 JPY
Interest and dividends received
12,000 JPY
84,000 JPY
Interest paid
-550,000 JPY
-525,000 JPY
Income taxes paid
-9,300,000 JPY
-8,375,000 JPY
Net cash provided by (used in) operating activities
7,081,000 JPY
-50,626,000 JPY
Cash flows from investing activities
Other, net
178,000 JPY
50,000 JPY
Net cash provided by (used in) investing activities
-8,821,000 JPY
-63,950,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
10,000,000 JPY
JPY
Repayments of long-term borrowings
-12,004,000 JPY
-2,004,000 JPY
Other, net
JPY
0 JPY
Net cash provided by (used in) financing activities
2,996,000 JPY
2,995,000 JPY
Effect of exchange rate change on cash and cash equivalents
2,820,000 JPY
3,191,000 JPY
Net increase (decrease) in cash and cash equivalents
4,076,000 JPY
-108,389,000 JPY
Cash and cash equivalents
566,074,000 JPY
561,997,000 JPY
340,795,000 JPY
449,184,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.